COPD Foundation and Evidera Awarded Best Personalized Medicine Advance or Application at the CARE Awards
BETHEDA, MD, USA, April 29, 2016 /EINPresswire.com/ -- Evidera and the COPD Foundation were awarded Best Personalized Medicine Advance or Application at Informa’s 2016 Clinical & Research Excellence (CARE) Awards, held on April 27 in Boston, MA.
Evidera, a global leader in health economics, outcomes research, market access, data analytics and epidemiology, and the Foundation’s COPD Biomarker Qualification Consortium (CBQC) were recognized for their work leading to the FDA’s qualification of plasma fibrinogen as a biomarker for clinical trials of COPD. This is the first biomarker for COPD and the seventh biomarker qualified by the FDA to date. The award recognizes the contributions of this dedicated team to advancing the promising field of personalized medicine. The judges commented that this project exemplified a successful public-private collaboration.
The CARE Awards were established to honor those who work in clinical research and development to make human lives better with new medicines. Jason Simeone, PhD, Research Scientist for Evidera and Debbie Merrill, Senior Director of CBQC were in attendance to accept the award.
“We enjoyed partnering with the CBQC on this project,” said Nancy Kline Leidy, PhD, Senior Vice President of Scientific Affairs for Evidera. “Jason and the Evidera analytics team were active in every step of the process, from design and implementation to interpretation and qualification. This CARE award recognizes the work the Evidera-CBQC partnership has accomplished to date, driven by a commitment to improving the efficiency and effectiveness of pharmaceutical trials in COPD. We look forward to continuing our work together.”
A complete listing of all CARE award winners can be found on Informa’s website. For more information on the COPD Foundation, visit www.copdfoundation.org.
About Evidera
Evidera, a wholly owned subsidiary of Symphony Technology Group, provides health economic, outcomes research, market access, data analytic and epidemiology services to life sciences organizations worldwide. For more information, visit www.evidera.com.
Evidera, a global leader in health economics, outcomes research, market access, data analytics and epidemiology, and the Foundation’s COPD Biomarker Qualification Consortium (CBQC) were recognized for their work leading to the FDA’s qualification of plasma fibrinogen as a biomarker for clinical trials of COPD. This is the first biomarker for COPD and the seventh biomarker qualified by the FDA to date. The award recognizes the contributions of this dedicated team to advancing the promising field of personalized medicine. The judges commented that this project exemplified a successful public-private collaboration.
The CARE Awards were established to honor those who work in clinical research and development to make human lives better with new medicines. Jason Simeone, PhD, Research Scientist for Evidera and Debbie Merrill, Senior Director of CBQC were in attendance to accept the award.
“We enjoyed partnering with the CBQC on this project,” said Nancy Kline Leidy, PhD, Senior Vice President of Scientific Affairs for Evidera. “Jason and the Evidera analytics team were active in every step of the process, from design and implementation to interpretation and qualification. This CARE award recognizes the work the Evidera-CBQC partnership has accomplished to date, driven by a commitment to improving the efficiency and effectiveness of pharmaceutical trials in COPD. We look forward to continuing our work together.”
A complete listing of all CARE award winners can be found on Informa’s website. For more information on the COPD Foundation, visit www.copdfoundation.org.
About Evidera
Evidera, a wholly owned subsidiary of Symphony Technology Group, provides health economic, outcomes research, market access, data analytic and epidemiology services to life sciences organizations worldwide. For more information, visit www.evidera.com.
Susan Potter Couch
Evidera
+1 301 664 7286
email us here